Essex Investment Management Co. LLC Has $1.57 Million Holdings in Paratek Pharmaceuticals Inc (PRTK)

Essex Investment Management Co. LLC raised its stake in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 63.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,634 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,267 shares during the period. Essex Investment Management Co. LLC owned about 0.23% of Paratek Pharmaceuticals worth $1,572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Legal & General Group Plc raised its position in Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares in the last quarter. Wells Fargo & Company MN raised its position in Paratek Pharmaceuticals by 9.9% in the 1st quarter. Wells Fargo & Company MN now owns 15,566 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,400 shares in the last quarter. ProShare Advisors LLC raised its position in Paratek Pharmaceuticals by 14.1% in the 2nd quarter. ProShare Advisors LLC now owns 16,191 shares of the specialty pharmaceutical company’s stock valued at $390,000 after purchasing an additional 2,005 shares in the last quarter. Nationwide Fund Advisors raised its position in Paratek Pharmaceuticals by 22.9% in the 2nd quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock valued at $322,000 after purchasing an additional 2,492 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in Paratek Pharmaceuticals by 7.2% in the 2nd quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 2,800 shares in the last quarter. 80.59% of the stock is currently owned by institutional investors.

PRTK has been the topic of several research analyst reports. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird reissued a “buy” rating and set a $40.00 target price on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. Guggenheim initiated coverage on Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They set a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Finally, ValuEngine lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $40.00.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/04/essex-investment-management-co-llc-has-1-57-million-holdings-in-paratek-pharmaceuticals-inc-prtk.html.

Shares of Paratek Pharmaceuticals Inc (NASDAQ PRTK) opened at $22.40 on Friday. Paratek Pharmaceuticals Inc has a 12-month low of $10.37 and a 12-month high of $29.00. The company has a current ratio of 11.88, a quick ratio of 11.88 and a debt-to-equity ratio of 0.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million. research analysts predict that Paratek Pharmaceuticals Inc will post -3.53 earnings per share for the current year.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

What are top analysts saying about Paratek Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Paratek Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit